Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases
This study is no longer recruiting patients.
Sponsored by: | National Center for Research Resources (NCRR) |
---|---|
Information provided by: | National Center for Research Resources (NCRR) |
Purpose
Recently a non-toxic system for whole body hyperthermia (WBH) used at the University of Wisconsin has been shown to induce soluble tumor necrosis factor-receptor (sTNF-R) I and II when patients are heated systemically to 41.8C for 60 minutes. This observation might provide a biological basis for the therapeutic application of WBH to rheumatoid diseases, for which there is a positive anecdotal clinical experience. Inherent in the hypothesis which is the basis for this protocol is the concept that the induction of TNF receptors by WBH may induce a remission in patients with active rheumatoid arthritis. Beyond clinical response the biological endpoint for this investigation includes cytokine levels, TNF levels, sTNF-R levels and changes in cellular TNF receptors.
Condition | Treatment or Intervention |
---|---|
Rheumatic Diseases |
Device: Whole body hyperthermia unit |
MedlinePlus related topics: Connective Tissue Disorders
Study Type: Interventional
Study Design: Treatment, Randomized, Parallel Assignment
Eligibility
Ages Eligible for Study: 18 Years - 65 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Location Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |